NCT03646968View on ClinicalTrials.gov

Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

June 1, 2025

Conditions
Non-Squamous Non Small Cell Lung Cancer
Interventions
DRUG

Anlotinib and Docetaxel

Patients who was Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer recieved the treatment of Anlotinib and Docetaxel (Anlotinib, 12mg, po,qd and Docetaxel 175mg/m2, ivgtt, every 21day)

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Yongchang Zhang

OTHER